On June 4, Veeva Systems declined 5.44% in pre-market trading, trading at $170.76/share, with trading volume of $223,900.

On the news front, the company reported fiscal Q1 results after market close, with non-GAAP earnings per share of $2.24, exceeding the consensus estimate of $2.13, while revenue came in at $882.9 million versus the expected $857.7 million. The company also raised its full-year fiscal 2027 adjusted EPS guidance to approximately $9.05, up from $8.85 previously, compared to the FactSet consensus of $8.86.

Despite the strong beat, the stock had rallied sharply in the sessions leading up to the earnings release — gaining nearly 9% on June 1 alone — as multiple client signings from Teva Pharmaceutical, Merck KGaA, and Kindeva, along with the launch of AI platform Falcon, drove optimistic positioning. With expectations largely priced in, the earnings release triggered concentrated profit-taking. Additionally, the Q2 revenue guidance of $902-$905 million and non-GAAP EPS of $2.21-$2.22, while slightly above consensus, suggested moderating sequential growth, adding to near-term selling pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)